2026 年 1 月 11 日（旧金山洲际酒店）——我们很高兴地宣布，恒瑞医药董事、执行副总裁 张连山博士 将在 ACCESS ASIA 药通亚洲 BD 论坛 @ JPM 2026 上发表演讲。
January 11, 2026 (InterContinental San Francisco) — We’re pleased to announce that Dr. Lianshan Zhang, Board Director and Executive Vice President at Hengrui Pharma, will speak at the ACCESS ASIA BD Forum @ JPM 2026.
由雅法主办的”ACCESS ASIA”论坛，延续ACCESS CHINA的成功经验，将亚洲领先的生物科技跨境平台拓展至更广阔领域，连接创新者与全球药企、投资机构和战略合作伙伴。论坛将于2026年1月11日在旧金山洲际酒店举行，为亚洲生物科技企业提供全球舞台，展示创新成果，促成战略合作，开拓商业发展新机遇。更多信息请访问：https://biotochina.org/
ACCESS ASIA, hosted by YAFO, builds on the success of ACCESS CHINA, expanding Asia’s leading cross-border biotech platform to connect innovators with global pharma, investors, and strategic partners. Taking place on January 11, 2026, at the InterContinental San Francisco, the forum provides a global stage for Asian biotech companies to showcase their innovation, foster partnerships, and explore new business development opportunities. View more information at: https://biotochina.org/
演讲嘉宾
About the speaker
张连山博士毕业于中国药科大学获药物化学专业并获得学士学位，后赴德国图宾根大学深造，获有机化学博士学位。博士毕业后赴美国田纳西州纳什维尔市范德比尔特大学微生物学与免疫学系, 任博士后研究员。
在加入恒瑞医药前，张连山博士先后在美国礼来和Marcadia Biotech等国际知名药企担任要职，其中在礼来先后任高级化学家、研究顾问及首席研究科学家等。自1988年至今，张连山博士从事多肽方法学和新药研发工作三十余年，在糖尿病治疗药物方面极有造诣。
加入恒瑞医药后任研发高管，带领团队研发了一系列具有国际竞争力的创新药，研发管线全面覆盖国际前沿靶点和存在巨大未满足临床需求的疾病领域。
Dr. Lianshan Zhang holds the position of Board Director and Executive Vice President of Jiangsu Hengrui Pharmaceuticals. Hengrui is widely recognized as the domestic leader in pharmaceutical R&D innovation in China. In 2010, Dr. Zhang joined Hengrui and took responsibility for the R&D strategy and management of dozens of NMEs across the globe. Prior to Hengrui, he was engaged in the discovery and development of peptide/protein therapeutics for the treatment of metabolic diseases at Eli Lilly and Marcadia Biotech. Dr. Zhang obtained his Ph.D. in Organic Chemistry at the University of Tubingen and conducted his post-doctoral research at Vanderbilt University.
关于ACCESS ASIA药通亚洲 BD Forum @ JPM 2026
About ACCESS ASIA BD Forum @ JPM 2026
2026 年 1 月 11 日， ACCESS ASIA 药通亚洲BD论坛 @ JPM 2026 将在美国旧金山洲际酒店正式举行。
ACCESS ASIA BD Forum @ JPM is scheduled to be held on January 11, 2026, at the InterContinental San Francisco, alongside the J.P. Morgan Healthcare Conference Week.
本次为期一天的论坛将呈现主题演讲、圆桌讨论、企业路演、公司展示，以及 1 对 1 合作洽谈，旨在连接亚洲领先的生物科技创新者与全球制药公司、投资机构及战略合作伙伴。
This full-day forum will feature keynote speeches, panel discussions, corporate presentations, company showcases, and 1-on-1 partnering meetings connecting Asia’s leading biotech innovators with global pharma, investors, and strategic partners.
会议名称: ACCESS ASIA 药通亚洲BD论坛 @ JPM 2026
时间 & 地点: 2026 年 1 月 11 日 | 旧金山洲际酒店
更多活动详情请至: https://biotochina.org/
Conference Name: ACCESS ASIA BD Forum @ JPM 2026
Date & Venue: January 11, 2026 | InterContinental San Francisco
View more information at: https://biotochina.org/
MORE INFORMATION
联系我们
Contact Us
如需报名参加 ACCESS ASIA 药通亚洲 BD 论坛 @ JPM
To register as an attendee for ACCESS ASIA BD Forum @ JPM, click the button below:
更多信息请联系：
For more information, please contact:
相文迪 Wendi Xiang | Wxiang@yafocapital.com
BioToChina.org 